share_log

Cue Biopharma Analyst Ratings

Cue Biopharma Analyst Ratings

CUE Biophma分析师评级
Benzinga Analyst Ratings ·  2022/11/21 05:08
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/21/2022 117.39% Piper Sandler → $7 Initiates Coverage On → Overweight
08/24/2022 210.56% Oppenheimer $26 → $10 Maintains Outperform
03/21/2022 707.45% Oppenheimer $32 → $26 Maintains Outperform
03/18/2022 707.45% Craig-Hallum $28 → $26 Maintains Buy
11/24/2020 831.68% Berenberg → $30 Initiates Coverage On → Buy
05/20/2020 831.68% Stifel $25 → $30 Maintains Buy
05/20/2020 893.79% Oppenheimer $27 → $32 Maintains Outperform
04/21/2020 676.4% Stifel $21 → $25 Maintains Buy
04/09/2020 552.17% Stifel → $21 Initiates Coverage On → Buy
03/06/2020 831.68% JMP Securities $22 → $30 Maintains Outperform
02/25/2020 738.51% Oppenheimer → $27 Initiates Coverage On → Outperform
01/28/2020 707.45% BTIG → $26 Initiates Coverage On → Buy
01/22/2020 583.23% JMP Securities → $22 Initiates Coverage On → Market Outperform
07/26/2019 303.73% Baird → $13 Initiates Coverage On → Outperform
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
11/21/2022 117.39% 派珀·桑德勒 → $7 开始承保 →超重
08/24/2022 210.56% 奥本海默 $26 → $10 维护 跑赢大盘
03/21/2022 707.45% 奥本海默 $32 → $26 维护 跑赢大盘
03/18/2022 707.45% 克雷格-哈勒姆 $28 → $26 维护 买
11/24/2020 831.68% 贝伦伯格 → $30 开始承保 →购买
05/20/2020 831.68% Stifel $25 → $30 维护 买
05/20/2020 893.79% 奥本海默 $27 → $32 维护 跑赢大盘
04/21/2020 676.4% Stifel $21 → $25 维护 买
04/09/2020 552.17% Stifel → $21 开始承保 →购买
03/06/2020 831.68% JMP证券 $22 → $30 维护 跑赢大盘
02/25/2020 738.51% 奥本海默 → $27 开始承保 →跑赢大盘
01/28/2020 707.45% BTIG → $26 开始承保 →购买
01/22/2020 583.23% JMP证券 → $22 开始承保 →市场跑赢大盘
07/26/2019 303.73% 贝尔德 → $13 开始承保 →跑赢大盘

What is the target price for Cue Biopharma (CUE)?

Cue Biophma(CUE)的目标价是多少？

The latest price target for Cue Biopharma (NASDAQ: CUE) was reported by Piper Sandler on November 21, 2022. The analyst firm set a price target for $7.00 expecting CUE to rise to within 12 months (a possible 117.39% upside). 4 analyst firms have reported ratings in the last year.

派珀·桑德勒于2022年11月21日报道了Cue Biophma(纳斯达克：CUE)的最新目标价。这家分析公司将目标价定为7美元，预计Cue将在12个月内上涨(可能上涨117.39%)。去年有4家分析公司公布了评级。

What is the most recent analyst rating for Cue Biopharma (CUE)?

Cue Biophma(CUE)的最新分析师评级是多少？

The latest analyst rating for Cue Biopharma (NASDAQ: CUE) was provided by Piper Sandler, and Cue Biopharma initiated their overweight rating.

纳斯达克的最新分析师评级是由派珀·桑德勒提供的，Cue Biophma启动了他们的增持评级。

When is the next analyst rating going to be posted or updated for Cue Biopharma (CUE)?

CUE Biophma(CUE)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cue Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cue Biopharma was filed on November 21, 2022 so you should expect the next rating to be made available sometime around November 21, 2023.

分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Cue Biophma的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Cue Biophma的上一次评级是在2022年11月21日提交的，所以你应该预计下一次评级将在2023年11月21日左右的某个时候提供。

Is the Analyst Rating Cue Biopharma (CUE) correct?

分析师评级CUE BIOPHMA(CUE)正确吗？

While ratings are subjective and will change, the latest Cue Biopharma (CUE) rating was a initiated with a price target of $0.00 to $7.00. The current price Cue Biopharma (CUE) is trading at is $3.22, which is within the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的Cue Biophma(CUE)评级是以0.00美元至7.00美元的目标价启动的。Cue Biophma(CUE)目前的交易价格为3.22美元，在分析师的预测区间内。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发